Ikena Oncology Inc
IKNA
Get informed when a big investor buys or sells
+ FollowMarket Cap$718.82M
Close$
$0.66
96.2% downside
Current Fair Value
96.2% downsideOvervalued by 96.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $718.82 Million |
|---|---|
| Enterprise Value | $645.19 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $0 |
| Beta | 0.5 |
| Outstanding Shares | 11,211,268,000 |
Return
| Return on Equity | -44.73% |
|---|---|
| Return on Assets | -40.36% |
| Return on Invested Capital | -36.83% |
Valuation & Multiples
| P/E Ratio | -1.49 |
|---|---|
| PEG | -6.43 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -13.47 |
| Enterprise Value to Net Income | -12 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
March 4, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 5.49%▼ 62.37% |
|---|---|
| Total Invested | $42.56M▲ 1.55% |
| Investors Holding | 42▼ 4.00% |
ESG Score
No data
About ImageneBio Inc
10 employees
CEO: Kristin Yarema Clinical-stage biotechnology company developing differentiated therapies for immunological/autoimmune & inflammatory (I&I) diseases, notably non‑depleting anti‑OX40 monoclonal antibody IMG‑007 in Phase 2b for atopic dermatitis